Joyce

Research Analyst at JPMorgan Chase & Co.

Calabarzon, Philippines

Joyce Chang is the Chair of Global Research for JP Morgan’s Corporate and Investment Bank, specializing in multi-sector coverage across equities, fixed income, currencies, commodities, emerging markets, derivatives, and structured finance. She began her career as an Emerging Markets Strategist and achieved 25 #1 individual rankings for Emerging Markets research in Institutional Investor surveys from 1997 to 2012, with J.P. Morgan’s global research team earning top firm distinction in 2017 and 2018. Prior to joining J.P. Morgan Chase in 1999, Chang served as Managing Director at Merrill Lynch and Salomon Brothers, and in 2014 was inducted into the Fixed Income Analyst Society Hall of Fame. Her professional credentials include longstanding leadership, recognized performance, and high-level industry honors.

Joyce's questions to Ultragenyx Pharmaceutical (RARE) leadership

Question · Q3 2025

Nov 4, 2025

Joyce asked about the expected enrollment curve for the Aurora supportive study for GTX-102 in Angelman syndrome, relative to the pivotal Aspire trial.

Answer

Howard Horn, Chief Financial Officer, stated that the Aurora trial is expected to enroll quickly due to high patient interest, despite not having a precise timeline. He highlighted its importance for understanding treatment safety and efficacy across a wider range of genotypes.

Ask follow-up questions

Fintool can predict RARE's earnings beat/miss a week before the call

Let Fintool AI Agent track Joyce for you

Get briefed when they ask questions on calls

Best AI Agent for Equity Research

Performance on expert-authored financial analysis tasks

Fintool-v490%

Claude Sonnet 4.555.3%

o348.3%

GPT 546.9%

Grok 440.3%

Qwen 3 Max32.7%

Try Fintool for free